Telix Pharmaceuticals (ASX:TLX) has reported robust commercial momentum in the quarter ended June 30, 2026, with group revenue of US$247 million, up 21 per cent year over year and 7 per cent from the prior quarter.
Precision Medicine led growth with US$202 million in revenue, a 30 per cent increase year over year and 9 per cent sequentially, while Telix Manufacturing Solutions contributed US$45 million.
The company said revenue is tracking toward the upper end of its financial year 2026 guidance. It expects revenue and other income to exceed US$1 billion, including a US$40 million non-refundable payment from Regeneron.
The company said the quarter featured several regulatory and clinical advances across both the Therapeutics and Precision Medicine portfolios.
The United States Food and Drug Administration provided alignment that allows the ProstACT global Phase 3 study of TLX591 Tx to advance to Part 2 in the U.S. Enrollment is progressing in multiple regions, and the program has regulatory approval to commence in China.
The OPTIMAL PSMA program completed enrollment in its OPTIMAL PSMA study and has begun dosing in the OPTIMAL-e Phase 2 study for earlier-stage disease. Telix also dosed the first patient in LUTEON, a pivotal trial of TLX250 Tx in clear cell renal cell carcinoma, and enrolled initial cohorts in IPAX BrIGHT, a pivotal trial of TLX101 Tx in recurrent glioblastoma.
On the imaging side, Telix reported rapid BiPASS enrollment for Illuccix and Gozellix, and completed patient enrollment in Japan for the registrational study of TLX591 Px with a New Drug Application in preparation.
The company said the FDA accepted the resubmitted NDA for Pixclara and granted a PDUFA goal date of September 11, 2026. Telix is also advancing its BLA resubmission for Zircaix and nearing completion of final CMC documentation.
Commercial and operational expansion continued with new manufacturing capacity and supply chain investments.
Telix recently opened a Telix Manufacturing Solutions (TMS) facility in North Melbourne in partnership with the Melbourne Theranostic Innovation Centre and completed a first GMP production run at TMS Brussels South. The company installed an ARTMS QUANTM irradiation system at TMS Yokohama as part of its plan to scale isotope production globally.
Corporate developments during the quarter included a strategic collaboration with Regeneron to jointly develop next-generation radiopharmaceutical therapies and the receipt of an initial US$40 million non-refundable payment. Telix also completed a refinancing by issuing US$600 million of convertible bonds due 2031 and repurchasing its 2029 bonds. Three new non-executive directors joined the board as part of succession planning.
Managing Director and Group CEO Dr Christian Behrenbruch said, “We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.”
